HK Stock Market Move | ASCLETIS-B (01672) opened more than 7% higher, as the company entered the field of obesity medication. The first batch of patients received medication in two Phase I clinical trials of ASC30.

ASCLETIS-B (01672) opened more than 7% higher, and as of the time of writing, it has risen by 7.62% to 1.13 Hong Kong dollars, with a trading volume of 122,000 Hong Kong dollars. In terms of news, Ge Li Pharmaceutical announced its entry into the field of obesity drugs. The company has recently completed the dosing of the first batch of patients in two Phase I clinical trials of ASC30 conducted in the United States. ASC30, independently developed by Ge Li, is the first and only small molecule GLP-1 receptor agonist that can be administered subcutaneously once a month or orally once daily for the treatment of obesity. Ge Li Pharmaceutical stated in the announcement that after a head-to-head comparison, ASC30 has demonstrated 2 to 3 times higher in-vitro efficacy against GLP-1R compared to Orforglipron. In intravenous glucose tolerance tests (IVGTT) conducted on non-human primates (NHPs), ASC30 (dose: 1.5 mg/kg) stimulated more insulin secretion compared to Orforglipron (dose: 6 mg/kg), with statistically significant differences.